Morgan Stanley cut its stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 65.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 157,835 shares of the biotechnology company’s stock after selling 304,286 shares during the quarter. Morgan Stanley owned about 0.42% of Spark Therapeutics worth $8,610,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. FMR LLC grew its stake in shares of Spark Therapeutics by 2.6% during the 2nd quarter. FMR LLC now owns 5,536,564 shares of the biotechnology company’s stock worth $458,206,000 after purchasing an additional 142,428 shares during the period. BlackRock Inc. grew its stake in shares of Spark Therapeutics by 5.6% during the 3rd quarter. BlackRock Inc. now owns 3,031,043 shares of the biotechnology company’s stock worth $165,344,000 after purchasing an additional 161,811 shares during the period. EcoR1 Capital LLC acquired a new position in shares of Spark Therapeutics during the 3rd quarter worth $45,661,000. Alliancebernstein L.P. grew its stake in shares of Spark Therapeutics by 38.3% during the 3rd quarter. Alliancebernstein L.P. now owns 531,184 shares of the biotechnology company’s stock worth $28,976,000 after purchasing an additional 147,158 shares during the period. Finally, Macquarie Group Ltd. grew its stake in shares of Spark Therapeutics by 21.2% during the 3rd quarter. Macquarie Group Ltd. now owns 508,856 shares of the biotechnology company’s stock worth $27,758,000 after purchasing an additional 88,931 shares during the period.
A number of equities research analysts recently commented on the stock. William Blair reissued a “buy” rating on shares of Spark Therapeutics in a research note on Tuesday, November 6th. Credit Suisse Group reissued a “hold” rating and issued a $44.00 price objective on shares of Spark Therapeutics in a research note on Friday. Cantor Fitzgerald set a $103.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Monday, December 3rd. Raymond James reissued a “buy” rating on shares of Spark Therapeutics in a research note on Monday, November 26th. Finally, ValuEngine raised shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 1st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $65.20.
Spark Therapeutics stock opened at $48.05 on Tuesday. Spark Therapeutics Inc has a 12-month low of $34.53 and a 12-month high of $96.59. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -6.30 and a beta of 2.06. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.36 and a current ratio of 10.71.
ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2019/02/12/spark-therapeutics-inc-once-stake-decreased-by-morgan-stanley.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Further Reading: How can investors find ex-dividend dates?
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.